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A bs tr ac t
Background
Prophylactic factor replacement in patients with hemophilia B improves outcomes but 
requires frequent injections. A recombinant factor IX Fc fusion protein (rFIXFc) with 
a prolonged half-life was developed to reduce the frequency of injections required.
Methods
We conducted a phase 3, nonrandomized, open-label study of the safety, efficacy, and 
pharmacokinetics of rFIXFc for prophylaxis, treatment of bleeding, and perioperative 
hemostasis in 123 previously treated male patients. All participants were 12 years of age 
or older and had severe hemophilia B (endogenous factor IX level of ≤2 IU per deciliter, 
or ≤2% of normal levels). The study included four treatment groups: group 1 received 
weekly dose-adjusted prophylaxis (50 IU of rFIXFc per kilogram of body weight to 
start), group 2 received interval-adjusted prophylaxis (100 IU per kilogram every 10 days 
to start), group 3 received treatment as needed for bleeding episodes (20 to 100 IU per 
kilogram), and group 4 received treatment in the perioperative period. A subgroup of 
group 1 underwent comparative sequential pharmacokinetic assessments of recombi-
nant factor IX and rFIXFc. The primary efficacy end point was the annualized bleeding 
rate, and safety end points included the development of inhibitors and adverse events.
Results
As compared with recombinant factor IX, rFIXFc exhibited a prolonged terminal half-
life (82.1 hours) (P<0.001). The median annualized bleeding rates in groups 1, 2, and 3 
were 3.0, 1.4, and 17.7, respectively. In group 2, 53.8% of participants had dosing inter-
vals of 14 days or more during the last 3 months of the study. In groups 1, 2 and 3, 90.4% 
of bleeding episodes resolved after one injection. Hemostasis was rated as excellent or 
good during all major surgeries. No inhibitors were detected in any participants receiv-
ing rFIXFc; in groups 1, 2, and 3, 73.9% of participants had at least one adverse event, 
and serious adverse events occurred in 10.9% of participants. These events were mostly 
consistent with those expected in the general population of patients with hemophilia.
Conclusions
Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleed-
ing rates in patients with hemophilia B. (Funded by Biogen Idec; ClinicalTrials.gov 
number, NCT01027364.)
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I n patients with severe hemophilia B, recurrent bleeding leads to painful hemarthro-ses, disabling hemophilic arthropathy, and 
other sequelae.1,2 Prophylactic replacement of co-
agulation factor IX is associated with improved 
clinical outcomes3-7; however, the relatively short 
half-lives of currently available factor IX products 
necessitate frequent intravenous injections (two or 
three times weekly) to maintain protective levels (at 
or above 1 IU per deciliter).8,9 The frequency of in-
jections is a considerable burden, cited by patients 
as a key deterrent to undertaking prophylactic 
treatment.10 Various strategies to reduce this bur-
den and improve the treatment of hemophilia B are 
under investigation,11,12 including the use of bio-
engineered coagulation factors, which may re-
quire less frequent injections,13-17 and gene-transfer 
therapy,18,19 a potentially curative treatment option.
To prolong the half-life and reduce the fre-
quency of injections, recombinant factor IX Fc 
fusion protein (rFIXFc), or eftrenonacog alfa, has 
been developed. The protein is composed of a 
single molecule of recombinant factor IX cova-
lently fused to the dimeric Fc domain of IgG1.
15,17 
With Fc fusion proteins, the neonatal Fc recep-
tor and the endogenous IgG recycling pathway 
delay lysosomal degradation of IgG and the fu-
sion proteins, recycling them back into circula-
tion and thus prolonging the plasma half-life.20,21 
The pharmacokinetics and safety of rFIXFc were 
previously evaluated in a single-dose, phase 1–2a 
clinical study involving patients with severe he-
mophilia B.17 Here we report the results of a 
phase 3 nonrandomized, open-label, multicenter 
study designed to compare the pharmacokinetics 
of rFIXFc with those of recombinant factor IX 
and to assess the safety and efficacy of repeated 
administration of rFIXFc for the prevention and 
treatment of bleeding in adolescents and adults 
with severe hemophilia B.
Me thods
Study Oversight
The protocol (available with the full text of this 
article at NEJM.org) was developed by the spon-
sor of the study, Biogen Idec, in collaboration 
with the Food and Drug Administration for a 
prelicensure study and was approved by the insti-
tutional review board at each participating cen-
ter. The study was conducted in accordance with 
the International Conference on Harmonization 
Guideline for Good Clinical Practice. Data were 
collected by the investigators and analyzed by the 
sponsor. All authors had access to the final data, 
participated in data analysis and interpretation, 
and vouch for the completeness and accuracy of 
the data and adherence to the study protocol. The 
first draft of the manuscript was written by 
three of the authors (two were employees of the 
sponsor, and the third a paid consultant to the 
sponsor) with input from all coauthors and with 
assistance from a medical writer funded by the 
sponsor. All authors participated in revising 
subsequent drafts of the manuscript and made 
the final decision to submit it for publication. 
Biogen Idec reviewed the manuscript and pro-
vided feedback to the authors.
Study Participants
Male patients 12 years of age or older with severe 
hemophilia B (≤2 IU of endogenous factor IX per 
deciliter) were eligible for inclusion in the study 
if they were receiving prophylaxis or had a his-
tory of at least eight bleeding events in the year 
before enrollment and had been previously treat-
ed with at least 100 injections of replacement 
factor IX (i.e., had accrued at least 100 exposure 
days). Patients were excluded if they had a history 
of development of inhibitors (i.e., neutralizing anti-
bodies) or anaphylaxis associated with factor IX or 
intravenous immunoglobulin. Patients with other 
coagulation disorders, uncontrolled infection with 
the human immunodeficiency virus (HIV), renal 
dysfunction, or active hepatic disease were also 
excluded from the study. All patients or their guard-
ians provided written informed consent.
Study Design
Participants were assigned to one of four treat-
ment groups (Fig. 1) by an investigator on the ba-
sis of the clinical site’s standard of care. Group 1 
received weekly prophylaxis with 50 IU of rFIXFc 
per kilogram of body weight to start, with the 
dose adjusted as needed; group 2 received interval-
adjusted prophylaxis with 100 IU of rFIXFc per 
kilogram at intervals of 10 days to start, with the 
interval adjusted as needed; group 3 received epi-
sodic (on-demand) treatment consisting of 20 to 
100 IU of rFIXFc per kilogram for bleeding epi-
sodes, with the dose adjusted according to bleed-
ing severity; and group 4 received treatment with 
rFIXFc as part of perioperative care. The dose (in 
group 1) and the interval (in group 2) were ad-
justed during the study to maintain a trough level 
of 1 to 3 IU per deciliter above baseline, or higher 
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if clinically necessary. The study was terminated 
when 53 participants had 50 or more rFIXFc ex-
posure days (i.e., administration of one or more 
rFIXFc injections in a 24-hour period) in conjunc-
tion with additional criteria (specified in the 
Supplementary Appendix, available at NEJM.org).
In a subgroup of participants in group 1, we 
performed sequential pharmacokinetic assess-
ments of an approved recombinant factor IX 
product (BeneFIX, Pfizer) and rFIXFc. At base-
line, a dose of 50 IU of recombinant factor IX 
per kilogram was injected and the pharmacoki-
netics were assessed for 96 hours, followed by a 
washout period of 120 hours and subsequent 
injection of 50 IU of rFIXFc per kilogram, with 
the pharmacokinetics assessed for 240 hours. 
Pharmacokinetic assessment in this subgroup 
was repeated at week 26, with results that were 
consistent with the baseline findings.
Outcome Measures
The primary efficacy end point was the per-patient 
annualized bleeding rate (the number of bleeding 
episodes per participant divided by the number of 
days in the efficacy period, multiplied by 365.25). 
Primary safety end points were the development of 
inhibitors (detected with the use of a Nijmegen-
modified Bethesda assay and confirmed on repeat 
123 Patients enrolled (all included in safety analysis)
Groups 1 and 2
Prior regimen: prophylactic or episodic
Group 3
Prior regimen: episodic
61 Were included in efficacy
analysis
1 Did not receive rFIXFc
1 Received only 1 dose
of rFIXFc
26 Were included in efficacy
analysis
2 Received an alternative
formulation of rFIXFc










4 Enrolled for surgery only
8 Enrolled from groups 1, 2, or 3
12 Were assigned to periopera-
tive management; dose
adjusted to type of surgery
(40–100 IU/kg)
3 Completed treatment
1 Did not complete treatment
owing to protocol violation
8 Returned to originally assigned
group after completing surgical
rehabilitation 




1 Did not complete treatment
owing to adverse event
29 Were assigned to interval-based
prophylaxis (100 IU/kg) 
starting every 10 days, 
PK-driven interval
27 Completed treatment
2 Did not complete treat-
ment owing to withdrawal
of consent
63 Were assigned to weekly prophy-
laxis, 50 IU/kg starting dose,
PK-driven dosing
59 Completed treatment
4 Did not complete treatment
1 Withdrew consent
1 Had adverse event
1 Was lost to follow-up
1 Had protocol violation
27 Were included in efficacy
analysis
Figure 1. Numbers of Patients Who Were Enrolled, Assigned to a Study Group, and Included in the Efficacy Analysis.
After screening, patients who had been receiving a prophylactic regimen could enroll in group 1 or 2, whereas those who had been receiving 
episodic treatment could enroll in any treatment group. The regimen history was unknown for 1 participant in group 1. Participants meeting 
the criteria for study inclusion who required major surgery could enter group 4 either directly or from group 1, 2, or 3. Complete pharmaco-
kinetic (PK) profiles for recombinant factor IX (rFIX) and recombinant factor IX Fc fusion protein (rFIXFc) were available for 22 participants 
at baseline. Two participants were withdrawn from the study because of adverse events (an infection and a motorcycle accident); both par-
ticipants were hospitalized in countries where the study drug could not be imported; therefore, the study treatment was discontinued and 
the patients were withdrawn from the study. Owing to a change in the manufacturing process for rFIXFc, participants who had received 
only an earlier form of rFIXFc were excluded from the efficacy analysis.
The New England Journal of Medicine 
Downloaded from nejm.org on December 4, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med nejm.org4
testing within 2 to 4 weeks if the titer reached 
0.6 Bethesda units or more per milliliter) and ad-
verse events. Secondary end points included phar-
macokinetic measures, the weekly dose of rFIXFc (in 
group 1), the dosing interval (in group 2), and the 
number of injections and dose per injection required 
to resolve a bleeding episode. Additional safety 
evaluations included assessment of non-neutraliz-
ing antibodies by means of an electrochemilumi-
nescence assay for rFIXFc-binding antibodies,22,23 
and measurements of laboratory markers (see the 
Supplementary Appendix). The rating of hemosta-
sis provided by the site investigator or surgeon dur-
ing the perioperative period was also evaluated.
Statistical Analysis
Efficacy analyses were performed with the use of 
data from participants who received one or more 
doses of rFIXFc during the efficacy period, not 
including the perioperative or surgical rehabilita-
tion period (i.e., the time from hospital discharge 
to 1 minute before the first prophylactic dose for 
groups 1 and 2 or, for group 3, the date of comple-
tion of the rehabilitation period). Safety analyses 
included data from participants who received one 
or more doses of rFIXFc or recombinant factor IX. 
Comparisons of prophylaxis with episodic treat-
ment (groups 1 and 2 vs. group 3) were based on 
annualized estimates of bleeding rates calculated 
with the use of a negative binomial regression 
model. Descriptive statistics included medians and 
interquartile ranges for groups 1, 2, and 3. Phar-
macokinetic measures of rFIXFc and recombinant 
factor IX were compared with the use of a repeated-
measures analysis-of-variance model with variables 
for study treatment and participant; 95% confi-
dence intervals were calculated for geometric 
means and for the intraparticipant ratio of rFIXFc 
to recombinant factor IX for each pharmacoki-
netic measure. For all tests, a two-sided alpha 
level of 5% was considered to indicate statistical 
significance. The incidence of inhibitor develop-
ment was assessed with the use of a group se-
quential design, with interim analyses conducted 
after at least 53 participants with 50 or more ex-
posure days to rFIXFc had undergone testing for 
the detection of inhibitors (see the Supplementary 
Appendix). The study was sufficiently powered to 
detect, with 95% confidence, a clinically mean-
ingful difference of 50% or more reduction in the 
annualized bleeding rate (group 1 vs. group 3) 
and to rule out an estimated incidence of inhibitor 
development of more than 10.65%.24
R esult s
Study Population
A total of 123 male patients were enrolled at 
50 investigational sites in 17 countries between 
January 22, 2010, and July 19, 2012. A total of 
115 participants (93.5%) completed the study 
(Fig. 1). Baseline characteristics (Table 1) showed 
a demographically diverse population, including 
many patients with HIV or hepatitis C virus in-
fection. The genotype profile was consistent with 
expectations in this population (with a missense 
mutation detected in 55% of participants). Enroll-
ment of the prophylaxis cohorts (groups 1 and 2) 
maintained a balanced distribution of prior regi-
mens and previous bleeding episodes. More than 
80% of participants who reported previous use of 
prophylaxis were receiving injections two or more 
times weekly. In groups 1, 2, and 3, the median 
durations of treatment were 51.6 weeks (range, 
<1 to 97), 58.3 weeks (range, <1 to 126), and 40.9 
weeks (range, 28 to 54), respectively, and the me-
dian numbers of exposure days were 55.0 (range, 
1 to 105), 38.0 (range, 1 to 71), and 16.0 (range, 
4 to 35), respectively. A total of 5243 rFIXFc injec-
tions were administered during the study, cor-
responding to 5144 exposure days (117.1 patient-
years of exposure). Overall, 96.6% of participants 
in the prophylaxis groups were adherent to their 
treatment regimen (i.e., took ≥80% of doses at 
the prescribed dose and ≥80% of doses at the 
prescribed interval) (95.1% in group 1 and 100% 
in group 2). Most participants self-administered 
rFIXFc at home.
Pharmacokinetic Measures
In the pharmacokinetics subgroup, 22 partici-
pants completed the baseline pharmacokinetic 
assessments for both recombinant factor IX and 
rFIXFc. The terminal half-life of rFIXFc was sig-
nificantly longer than that of recombinant factor 
IX (geometric mean, 82.1 vs. 33.8 hours; P<0.001) 
(Fig. 2, and Tables S1 and S2 in the Supplemen-
tary Appendix). The incremental recovery levels 
for rFIXFc and recombinant factor IX were simi-
lar (0.92 and 0.95 IU per deciliter per interna-
tional unit per kilogram, respectively). The time 
to reach a factor IX level of 1 IU per deciliter (1%) 
was 11.2 days with rFIXFc and 5.1 days with re-
combinant factor IX (Fig. 2, and Table S1 in the 
Supplementary Appendix). The pharmacokinetic 
findings at week 26 were consistent with those at 
baseline (data not shown).
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Efficacy
Prophylactic treatment significantly reduced the 
annualized rate of bleeding in group 1 (by 83%) 
and group 2 (by 87%) as compared with the rate 
in the group receiving episodic treatment, accord-
ing to estimates from a negative binominal re-
gression model (3.12, 2.40, and 18.67 for groups 
1, 2, and 3, respectively; P<0.001) (Table 2). The 
median weekly rFIXFc dose with weekly prophy-
laxis (group 1) was 45 IU per kilogram (starting 
dose, 50 IU per kilogram), and the median dos-
ing interval with interval-adjusted prophylaxis 
Table 1. Baseline Characteristics of the Study Participants.*
Characteristic















Median 28 33 36 30
Range 12–71 12–62 14–64 12–71
Weight — kg
Median 70.2 76.0 65.0 72.0
Range 45.2–186.7 50.0–128.0 45.0–91.7 45.0–186.7
Race or ethnic group — no. (%)
White 41 (65.1) 18 (62.1) 11 (40.7) 70 (58.8)
Black 7 (11.1) 2 (6.9) 1 (3.7) 10 (8.4)
Asian 7 (11.1) 7 (24.1) 14 (51.9) 28 (23.5)
Other‡ 8 (12.7) 2 (6.9) 1 (3.7) 11 (9.2)
Geographic location — no. (%)
Europe 21 (33.3) 12 (41.4) 2 (7.4) 35 (29.4)
North America 18 (28.6) 7 (24.1) 11 (40.7) 36 (30.3)
Other§ 24 (38.1) 10 (34.5) 14 (51.9) 48 (40.3)
Factor IX level — no. (%)
<1 IU/dl 50 (79.4) 22 (75.9) 26 (96.3) 98 (82.4)
1–2 IU/dl 13 (20.6) 7 (24.1) 1 (3.7) 21 (17.6)
Prestudy factor IX therapy — no. (%)¶
Prophylaxis 33 (53.2) 15 (51.7) 0 48 (40.7)
Episodic treatment 29 (46.8) 14 (48.3) 27 (100.0) 70 (59.3)
Estimated no. of bleeding episodes in prior  
12 mo
Overall
Median 10.5 10.0 18.0 12.0
Range 0–70 0–100 5–50 0–100
With prior prophylaxis
Median 2.5 2.0 NA 2.0
Range 0–21 0–7 NA 0–21
With prior episodic treatment 23.0 (6–70) 25.0 (10–100) 18.0 (5–50) 22.0 (5–100)
≥1 Target joint — no. (%) 36 (57.1) 8 (27.6) 14 (51.9) 58 (48.7)
HIV-positive — no. (%) 5 (7.9) 1 (3.4) 2 (7.4) 8 (6.7)
HCV-positive — no. (%) 38 (60.3) 15 (51.7) 14 (51.9) 67 (56.3)
* HCV denotes hepatitis C virus, HIV human immunodeficiency virus, and NA not applicable.
† The four participants who were enrolled only in the perioperative surgery group are not included.
‡ Other races and ethnic groups include Native American or Alaska Native, Hispanic, and mixed races (e.g., white and Asian 
or white and black).
§ Other locations included Australia, Brazil, China, India, Japan, and South Africa.
¶ The prestudy regimen was unknown for one participant in group 1; percentages were calculated on the basis of participants 
for whom data were complete.
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(group 2) was 12.5 days (starting interval, 10 days) 
(Table 2, and Fig. S1 in the Supplementary Appen-
dix). Among the participants in group 2 who were 
in the study for 6 or more months, 14 participants 
(53.8%) had a dosing interval that was 14 or more 
days during the last 3 months of the study.
The reduction in the annualized bleeding rate 
with prophylaxis as compared with episodic 
treatment was consistent across all demographic 
and disease-based subgroups in prespecified sub-
group analyses (Fig. 3 and Table 2). Participants 
who received prophylaxis and had previously 
received episodic treatment had lower median 
annualized bleeding rates during the study than 
during the 12-month period before study entry 
(group 1, 2.5 vs. 23.0; group 2, 1.9 vs. 25.0); this 
reduction in bleeding rates was not observed in 
participants who continued to receive episodic 
treatment (group 3, 17.7 vs. 18.0). Participants in 
groups 1, 2, and 3 with the highest bleeding fre-
quency before study entry (≥36 bleeding episodes) 
had median annualized bleeding rates of 2.05, 
2.76, and 29.43, respectively, while enrolled in the 
study. Among the participants receiving prophy-
laxis, 23.0% in group 1 and 42.3% in group 2 
had no bleeding episodes during the study.
A total of 636 bleeding episodes, primarily 
spontaneous joint bleeding, occurred during the 
efficacy period. One injection was sufficient to 
resolve 90.4% of bleeding episodes; 97.3% were 
resolved with one or two injections. The median 
dose per injection required to resolve bleeding 
episodes was 46 IU per kilogram (Table S3 in 
the Supplementary Appendix). For bleeding epi-
sodes that required more than one injection for 
resolution, the median interval between the first 
and second injection was 45 hours. In 14 major 
surgeries performed in 12 participants, including 
5 knee replacements, the hemostatic response 
during the perioperative period was rated by in-
vestigators or surgeons as excellent (for 13 surger-
ies) or good (for 1).
Safety
Inhibitors were not detected in any participants 
with test results that could be evaluated, including 
55 participants with 50 or more exposure days, for 
whom the inhibitor incidence was 0% (95% con-
fidence interval [CI], 0 to 6.5); the inhibitor inci-
dence overall was also 0% (95% CI, 0 to 3.0). In the 
safety-analysis population, non-neutralizing anti-
bodies were detected at a low titer or at a borderline-
positive titer (defined as a maximum level two 
times as high as the lowest measurable titer) in 
three participants before exposure to rFIXFc; all 
three had negative test results during the study. 
One participant who had a borderline-negative 
test result (two of three screening-assay results 
just below the limit of detection) before exposure 
to rFIXFc had a borderline-positive result at the 
end of study. These transient and low antibody 
titers did not affect the pharmacokinetics of 
rFIXFc and had no discernible clinical effect.
Among the 119 participants in groups 1, 2, 


































Figure 2. Duration of Factor IX Activity with Recombinant 
Factor IX and rFIXFc at a Dose of 50 IU per Kilogram  
of Body Weight.
The data presented represent factor IX activity (mean 
±SD) for each treatment group. The dashed lines indi-
cate factor IX trough levels of 1 IU per deciliter (1%) 
and 3 IU per deciliter (3%). Pharmacokinetic measures 
were assessed for 22 participants at baseline. The ter-
minal half-life of rFIXFc (geometric mean, 82.1 hours) 
was significantly longer than that of rFIX (geometric mean, 
33.8 hours, based on a 96-hour sampling schedule) 
(P<0.001). The half-life of rFIX, calculated on the basis 
of the traditional 48-hour pharmacokinetic sampling 
schedule, was 17.04 hours (95% confidence interval [CI], 
15.89 to 18.26), which is similar to previously reported 
48-hour data.25 Clearance was significantly lower for 
rFIXFc (3.2 ml per hour per kilogram of body weight; 
95% CI, 2.8 to 3.6 ) than for rFIX (6.3 ml per hour per kilo-
gram; 95% CI, 5.6 to 7.1). The dose-normalized area un-
der the curve was 31.3 IU × hour per deciliter per inter-
national unit per kilogram (95% CI, 27.9 to 35.2) and 
15.8 IU × hour per deciliter per IU per kilogram (95% CI, 
14.0 to 17.7) for rFIXFc and rFIX, respectively. Times to 
1 and 3 IU per deciliter above baseline were 11.2 days 
(95% CI, 10.2 to 12.4) and 5.8 days (95% CI, 5.1 to 6.6), 
respectively, for rFIXFc versus 5.1 days (95% CI, 4.6 to 
5.7) and 2.8 days (95% CI, 2.6 to 3.1), respectively, for 
rFIX (P<0.001).
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verse event during the rFIXFc treatment period 
(excluding adverse events that occurred during the 
perioperative period) (Table S4 in the Supple-
mentary Appendix). The most common adverse 
events (with an incidence ≥5% in a pooled analy-
sis of groups 1, 2, and 3) were nasopharyngitis, 
influenza, arthralgia, upper respiratory tract infec-
tion, headache, and hypertension. The majority of 
these events were judged by the investigators to 
be unrelated or unlikely to be related to treatment 
with rFIXFc. Thirteen of the 119 participants 
(10.9%) had at least one serious adverse event. One 
participant had a single serious adverse event that 
was considered to be possibly related to treatment 
with rFIXFc. In this participant, who had a history 
of painful hematuria, an obstructive clot developed 
in the urinary collecting system. The clot resolved 
with medical management, and the participant 
continued with the study treatment and com-
pleted the study. There were no reports of vascu-
lar thrombotic events, serious hypersensitivity, 
or anaphylaxis, and there were no deaths during 
the study. No unique safety concerns were iden-
tified in participants undergoing major surgery.
Discussion
This phase 3 study confirmed data from a phase 
1–2a study showing the prolonged half-life of 
rFIXFc, as compared with recombinant factor 
IX,17 and showed that rFIXFc had an acceptable 
safety profile and was effective in the prevention 
and treatment of bleeding in previously treated 
adolescents and adults with severe hemophilia B. 
All participants who received prophylactic rFIXFc, 
including those with a high frequency of bleeding 
before study entry, had marked reductions in the 
annualized bleeding rate, as compared with pa-
tients who received episodic treatment. Before 
study entry, 80% or more of participants treated 
prophylactically required injections at least two 
times per week, whereas during the study, pro-
phylaxis was effective with injections adminis-
tered every 1 to 2 weeks. These dosing intervals 
are longer than those observed in previous trials 
of recombinant factor IX.25-27
The neonatal Fc-receptor–mediated extension 
of half-life was apparent in the intraparticipant 
comparison of the pharmacokinetics of rFIXFc 
and recombinant factor IX. The terminal half-life 
of rFIXFc was 82.1 hours. The terminal half-life 
for recombinant factor IX (33.8 hours), which we 
calculated by means of pharmacokinetic sampling 
over the course of 96 hours, was substantially 
longer than that reported in some previous studies 
on the basis of 48-hour sampling (terminal half-
life, approximately 18 hours),14,16,25,26,28 whereas 
it was more in line with the terminal half-life in 
studies that performed 72-hour sampling (termi-
nal half-life, 21.3 to 33.4 hours).13,27,29-31 When we 
analyzed the pharmacokinetics of recombinant 
factor IX on the basis of sampling for only 48 hours 
(Table S2 in the Supplementary Appendix), the 
terminal half-life was 17.0 hours, which is consis-
tent with the results of the studies using 48-hour 
sampling, thus confirming the method used in our 
analysis of recombinant factor IX. All clearance-
dependent pharmacokinetic measures in this study 
were prolonged with rFIXFc as compared with 
recombinant factor IX and remained stable over 
the course of long-term treatment, suggesting 
that the pharmacokinetics of rFIXFc may be used 
to individualize dosing regimens.
Adverse events observed in this study were 
consistent with those expected in the popula-
tion of persons with hemophilia,27 and the rate of 
study completion was high (93.5%). Inhibitors of 
rFIXFc were not detected in any participant, in-
cluding 55 participants who were followed for 
50 or more exposure days. Inhibitors generally 
develop within the first 50 exposure days of 
factor IX replacement therapy32; they can pose 
a challenge to the establishment of hemostasis 
and can be associated with anaphylaxis.33,34 
Since participants with a history of inhibitors to 
factor IX were excluded from the study, which 
was limited to previously treated patients (a pa-
tient population at low risk for the development 
of inhibitors),35,36 further clinical study is need-
ed to assess the likelihood of the development of 
inhibitors of rFIXFc in previously untreated pa-
tients and to determine whether patients with a 
history of the development of inhibitors to factor 
IX will benefit from rFIXFc.
Although the incidence of non-neutralizing 
antibodies in patients with hemophilia B is un-
known, such antibodies have been reported in 
up to 30% of patients with hemophilia A.37,38 In 
this study, non-neutralizing antibodies were ob-
served at low titers in 3% of participants before 
treatment with rFIXFc began, but their presence 
was transient and had no discernible effect on the 
pharmacokinetics of rFIXFc or on bleeding rates. 
The clinical significance of non-neutralizing anti-
bodies is not well understood and requires further 
longitudinal study.
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Clinical trial design for patients with hemo-
philia B presents a challenge to investigators 
owing to the small population of patients and 
ethical considerations that preclude the conduct 
of placebo-controlled studies in which partici-
pants are unaware of the group assignment.39,40 
Although our study included a controlled intra-
participant comparison of the pharmacokinetics 
of rFIXFc and recombinant factor IX, it did not 
include an active-comparator control group for 
the evaluation of trial end points. The study was 
designed to allow a participant’s treatment regi-
men to be consistent with current clinical practice. 
It would have been unethical to allow a participant 
who had been receiving a prophylactic regimen to 
undergo randomization to an episodic regimen, 
given that prophylaxis is the standard of care in 
many regions of the world. Thus, treatment assign-
ments were performed in a nonrandomized man-
ner, with every effort made to balance the pro-
phylactic treatment groups with respect to prior 
regimens and the history of bleeding.
Since determination of the efficacy of prophy-
laxis was based on nonrandomized comparisons 
with episodic treatment, there is potential for 
bias. However, multiple subgroup analyses sup-
ported the primary efficacy results, including an 
analysis limiting the comparison to participants 
who had received episodic treatment before study 
entry, which revealed a reduction in the annual-
ized bleeding rate during prophylactic therapy 
that was similar to that observed in the primary 
analysis. There is evidence that participants with 
prior episodic treatment and a high frequency of 
bleeding episodes may have preferentially elected 
to enter the prophylaxis groups (i.e., bleeding 
rates in the 12 months preceding study entry were 
higher among participants in groups 1 and 2 who 
had been receiving episodic treatment than among 
participants in group 3). Allowing participants to 
elect to enter a prophylactic group may introduce 
self-selection bias. The potential for confounding 
remains; however, it is unlikely that the magni-
tude of the reduction in bleeding rates with pro-
phylaxis as compared with episodic treatment is 
the result of confounding alone.
Table 2. Efficacy End Points for Weekly Prophylaxis, Interval-Adjusted Prophylaxis, and Episodic Treatment.
End Point






 Group 3: Episodic 
Treatment
(N = 27)
Annualized bleeding rate (95% CI)* 3.12 (2.46–3.95) 2.40 (1.67–3.47) 18.67 (14.01–24.89)
Reduction in annualized bleeding rate 
vs. group 3 — %*
83 (<0.001) 87 (<0.001)
Annualized bleeding rate
Overall 3.0 (1.0–4.4) 1.4 (0.0–3.4) 17.7 (10.8–23.2)
Spontaneous 1.0 (0.0–2.2) 0.9 (0.0–2.3) 11.8 (2.6–19.8)
Traumatic 1.0 (0.0–2.1) 0.0 (0.0–0.8) 2.2 (0.0–6.8)
Joint 1.1 (0.0–4.0) 0.4 (0.0–3.2) 13.6 (6.1–21.6)
Spontaneous 1.0 (0.0–2.1) 0.0 (0.0–1.7) 5.1 (2.6–17.3)
Traumatic 0.0 (0.0–1.1) 0 1.3 (0.0–3.6)
Muscle 0.0 (0.0–1.0) 0 4.0 (1.0–6.8)
Spontaneous 0 0 1.0 (0.0–3.6)
Traumatic 0 0 1.1 (0.0–2.7)
Baseline trough level of factor IX†
<1 IU/dl
Median 2.6 1.1 18.5
Interquartile range 1.0–4.1 0.0–2.9 13.2–23.2
1–2 IU/dl
Median 4.5 3.4 7.7
Interquartile range 0.0–6.4 0.0–5.7 7.7–7.7
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This study was not designed to compare the 
two prophylactic regimens. Both the weekly dos-
ing and interval-adjusted dosing regimens re-
sulted in significantly reduced annualized rates 
of bleeding, as compared with episodic treat-
ment. Whether one approach to dosing is supe-
rior to the other cannot be determined on the 
basis of this study. In clinical practice, the two 
approaches may offer patients the choice between 
more frequent dosing (e.g., weekly dosing), which 
would maintain higher trough levels of factor IX, 
providing greater protection, and less frequent 
dosing, which would result in lower trough 
levels but would reduce the required frequency 
of injections.
In conclusion, this study showed that rFIXFc 
is safe and effective for the treatment and pre-
vention of bleeding events, including those in-
curred during major surgeries, in previously 
treated adolescents and adults with hemophilia B. 
Fc fusion did not impair factor IX activity or 
result in increased immunogenicity. The pro-
longed half-life of rFIXFc allowed for effective 
prophylaxis, with injections every 1 to 2 weeks. 
Table 2. (Continued.)
End Point






 Group 3: Episodic 
Treatment
(N = 27)




Last 6 mo in study
Median 40.7
Range 21.3–82.7
Last 3 mo in study
Median 40.5
Range 16.7–87.6
Interval for interval-adjusted prophylaxis 




Last 6 mo in study
Median 13.8
Range 7.8–19.1
Last 3 mo in study
Median 14.0
Range 7.7–20.8
* Annualized bleeding rates (the number of bleeding episodes per participant divided by the number of days in the efficacy 
period, multiplied by 365.25) were calculated with the use of the negative binomial regression model to control for par-
ticipants’ time in the study. CI denotes confidence interval. P<0.001 for the rate reductions in groups 1 and 2 as com-
pared with group 3.
† The baseline trough level was the minimum factor IX level measured in screening and baseline laboratory tests. In 
groups 1, 2, and 3, the numbers of participants with trough levels of less than 1 IU per deciliter were 48, 21, and 26,  
respectively, and the numbers with levels between 1 and 2 IU per deciliter were 13, 5, and 1, respectively.
‡ Changes in pharmacokinetically driven dosing for groups 1 and 2 were allowed to achieve trough levels that were 1 to  
3 IU per deciliter above baseline. If participants had two breakthrough spontaneous bleeding episodes in a rolling 
3-month period, the dose (in group 1) or the interval (in group 2) could be adjusted to provide more protection. The 
numbers of participants who remained in the study for 9 or more months were 58 in group 1 and 26 in group 2; the 
numbers were the same for participants who remained in the study for 6 or more months.
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The potential for higher trough levels of rFIXFc 
or longer intervals between doses may lead to 
greater use of prophylaxis among patients with 
hemophilia B.
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Figure 3. Annualized Bleeding Rate in Groups 1, 2, and 3 and Subgroups of Group 1.
The results of all subgroup analyses were consistent with the results of the primary efficacy analysis, with a reduc-
tion in bleeding rates in groups 1 and 2 and all prespecified subgroups of group 1. Group 1 was the only group in 
which there was a sufficient number of participants to display subgroup analyses graphically. The bars within the 
boxes indicate the medians; the ends of the boxes represent the interquartile range from 25 to 75%, and the bars 
outside the boxes represent the range from 10 to 90%; circles represent outliers (individual participants). The pre-
study treatment regimen was unknown for one participant in group 1.
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